Literature DB >> 21643037

Helicobacter pylori eradication: A new, single-capsule bismuth-containing quadruple therapy.

Javier P Gisbert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21643037     DOI： 10.1038/nrgastro.2011.84

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  11 in total

Review 1.  Helicobacter pylori infection.

Authors:  Sebastian Suerbaum; Pierre Michetti
Journal:  N Engl J Med       Date:  2002-10-10       Impact factor: 91.245

2.  Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis.

Authors:  E Gené; X Calvet; R Azagra; J P Gisbert
Journal:  Aliment Pharmacol Ther       Date:  2003-05-01       Impact factor: 8.171

Review 3.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

4.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

5.  Quadruple or triple therapy to eradicate H pylori.

Authors:  Byoung Hwan Lee; Nayoung Kim
Journal:  Lancet       Date:  2011-02-21       Impact factor: 79.321

6.  Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.

Authors:  Peter Malfertheiner; Franco Bazzoli; Jean-Charles Delchier; Krysztof Celiñski; Monique Giguère; Marc Rivière; Francis Mégraud
Journal:  Lancet       Date:  2011-02-21       Impact factor: 79.321

Review 7.  Sequential therapy for Helicobacter pylori eradication: a critical review.

Authors:  Javier P Gisbert; Xavier Calvet; Anthony O'Connor; Francis Mégraud; Colm A O'Morain
Journal:  J Clin Gastroenterol       Date:  2010 May-Jun       Impact factor: 3.062

Review 8.  Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.

Authors:  Jay Luther; Peter D R Higgins; Phillip S Schoenfeld; Paul Moayyedi; Nimish Vakil; William D Chey
Journal:  Am J Gastroenterol       Date:  2009-09-15       Impact factor: 10.864

9.  Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study.

Authors:  C O'Morain; T Borody; A Farley; W A De Boer; C Dallaire; R Schuman; J Piotrowski; C A Fallone; G Tytgat; F Mégraud; J Spénard
Journal:  Aliment Pharmacol Ther       Date:  2003-02       Impact factor: 8.171

10.  Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial.

Authors:  Loren Laine; Richard Hunt; Hala El-Zimaity; Bich Nguyen; Michael Osato; Jean Spénard
Journal:  Am J Gastroenterol       Date:  2003-03       Impact factor: 10.864
View more
  9 in total

1.  Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.

Authors:  J P Gisbert; A Perez-Aisa; L Rodrigo; J Molina-Infante; I Modolell; F Bermejo; M Castro-Fernández; R Antón; B Sacristán; A Cosme; J Barrio; Y Harb; M Gonzalez-Barcenas; M Fernandez-Bermejo; A Algaba; A C Marín; A G McNicholl
Journal:  Dig Dis Sci       Date:  2013-10-15       Impact factor: 3.199

2.  In vitro cytotoxicity of surface modified bismuth nanoparticles.

Authors:  Yang Luo; Chaoming Wang; Yong Qiao; Mainul Hossain; Liyuan Ma; Ming Su
Journal:  J Mater Sci Mater Med       Date:  2012-07-17       Impact factor: 3.896

3.  Glutathione and multidrug resistance protein transporter mediate a self-propelled disposal of bismuth in human cells.

Authors:  Yifan Hong; Yau-Tsz Lai; Godfrey Chi-Fung Chan; Hongzhe Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-03       Impact factor: 11.205

Review 4.  Overview of the phytomedicine approaches against Helicobacter pylori.

Authors:  Filipa F Vale; Mónica Oleastro
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

5.  Rescue Therapy for Helicobacter pylori Infection 2012.

Authors:  Javier P Gisbert
Journal:  Gastroenterol Res Pract       Date:  2012-02-28       Impact factor: 2.260

6.  Metallochaperone UreG serves as a new target for design of urease inhibitor: A novel strategy for development of antimicrobials.

Authors:  Xinming Yang; Mohamad Koohi-Moghadam; Runming Wang; Yuen-Yan Chang; Patrick C Y Woo; Junwen Wang; Hongyan Li; Hongzhe Sun
Journal:  PLoS Biol       Date:  2018-01-10       Impact factor: 8.029

Review 7.  Current and potential applications of bismuth-based drugs.

Authors:  Donal M Keogan; Darren M Griffith
Journal:  Molecules       Date:  2014-09-23       Impact factor: 4.411

8.  Bismuth Reduces Cisplatin-Induced Nephrotoxicity Via Enhancing Glutathione Conjugation and Vesicular Transport.

Authors:  Hui Jiang; Yifan Hong; Guorong Fan
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

9.  Bismuth antimicrobial drugs serve as broad-spectrum metallo-β-lactamase inhibitors.

Authors:  Runming Wang; Tsz-Pui Lai; Peng Gao; Hongmin Zhang; Pak-Leung Ho; Patrick Chiu-Yat Woo; Guixing Ma; Richard Yi-Tsun Kao; Hongyan Li; Hongzhe Sun
Journal:  Nat Commun       Date:  2018-01-30       Impact factor: 14.919
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.